EXHIBIT 10.6
CONSULTING AGREEMENT
Consulting Agreement
THIS CONSULTING AGREEMENT, having an effective date of October 9, 2000 is made
between ▇▇▇▇▇▇▇ (▇▇▇) ▇. ▇▇▇▇▇▇▇, doing business as ▇▇▇▇▇▇▇ Regulatory
Consulting (herein referred to as "Consultant"), ▇▇▇▇▇ ▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇,
▇▇ ▇▇▇▇▇ (SS####-##-####) and Phage Therapeutics International Inc., having a
mailing address as ▇▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ ▇▇, ▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇-▇▇▇▇ (herein referred
to as "Client")
The parties agree as follows:
(1) Term. The Term of this Agreement shall be from October 16, 2000 through
October 16, 2001. Either party may terminated this agreement
immediately with cause, or upon 30 days prior to written notice without
cause.
(2) Service to be Provided. Consultant shall provide regulatory consulting
services related to FDA requirements for submission of Investigational
New Drug Applications (INDs) to conduct clinical studies used to
support the development and marketing of Client's products.
(3) Compensation. During the term of this Agreement, Client shall pay
Consultant a fee of $120 per hour, for approximately 40 hours per
month, the total amount payable monthly upon receipt of an invoice for
services to be sent to the attention of ▇▇▇▇▇▇▇ Honour, PhD. The
invoices submitted by Consultant shall provide the date and a brief
description of services rendered, and Client shall provide payment for
approved services within thirty (30 ) days of receipt of such invoice.
Consultant understands that she is an independent contractor and will
be responsible for her own withholding taxes and social security
deductions.
In addition, Client shall reimburse Consultant for actual and necessary
out-of-pocket expenses incurred (when pre-approved by Client), where
such expenses are related to services rendered under this Agreement,
such as overnight travel.
(4) Confidential Information and Property. Consultant agrees that she will
not disclose or use any Confidential Information related to Client, or
any property of Client, except as Client shall direct as described in
the "Confidential Disclosure Agreement" signed by both parties
(Attachment A).
(5) Entire Agreement. This agreement (and its attachment A) expresses the
entire understanding between the parties on the subject matter hereof.
The provisions of this agreement may not be waived or modified except
by a writing signed by the party against whom enforcement is sought. No
waiver of breach shall constitute a subsequent waiver of any subsequent
breach, and if any provisions of this agreement are held to be invalid
or unenforeceable, the remaining provisions shall remain valid and
enforceable.
Client:
-------
▇▇▇▇▇▇▇ Regulatory Consulting: Phage Therapeutics International, Inc.
By /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ /s/ By /s/ ▇▇▇▇▇▇▇ ▇. Honour /s/
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇. Honour
Its Sole Proprietor Its Director
Date Signed 10-09-00 Date Signed 10-16-00